
Natco Pharma Q3 net increases 27%
The Hindu
Drugmaker Natco Pharma reported consolidated net profit increased 27% to ₹80.4 crore for the quarter ended December from ₹63.40 crore of the year earlier period.
The higher net profit came on the back of a 53% increase in total income to ₹590.7 crore (₹386 crore), which included product licensing income. During the quarter, there was a one-time expense against the product licensing income. The company has declared a third interim dividend of ₹2 per equity share of ₹2 each.
Driving the growth in revenue was increase in the share of Formulations exports, including profit share, licensing and foreign subsidiaries, to ₹383.1 crore (₹162.1 crore). Other operating income and non-operating income increased to ₹45.3 crore (₹5.9 crore).

India’s trade data for November reveals continued resilience in exports despite mounting U.S. tariffs on several key products. This is particularly significant given that the U.S. remains India’s largest export partner by a substantial margin. Interestingly, overall exports have not only grown, but shipments specifically to the U.S. have also rebounded.












